TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2026

Conditions
Breast Cancer
Interventions
DRUG

ARV-471

Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until the recommended phase 2 dose (RP2D) determined, cycles lasting 28 days

DRUG

Abemaciclib

Daily oral dosages of Abemaciclib continuously, cycles lasting 28 days

Trial Locations (36)

10060

Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia, Candiolo

28027

Clinica Universidad de Navarra, Madrid

Clínica Universidad de Navarra, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

31008

Clinica Universidad de Navarra, Pamplona

33607

Moffitt Cancer Center - International Plaza, Tampa

33612

Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center, Tampa

Moffitt McKinley Hospital, Tampa

41013

Hospital Universitario Virgen Del Rocio, Seville

62269

Siteman Cancer Center - WUPI, Shiloh

63031

Siteman Cancer Center - North County, Florissant

63110

Barnes-Jewish Hospital, St Louis

Washington University School of Medicine - Siteman Cancer Center, St Louis

Washington University School of Medicine, St Louis

63129

Siteman Cancer Center - South County, St Louis

63141

Siteman Cancer Center - West County, Creve Coeur

63376

Siteman Cancer Center - St Peters, City of Saint Peters

77030

U.T. MD Anderson Cancer Center, Investigational Pharmacy Services - Unit 376, Houston

U.T. MD Anderson Cancer Center, Houston

University of Texas MD Anderson Cancer Center, Houston

94158

UCSF Medical Center at Mission Bay, San Francisco

94304

Stanford Women's Cancer Center, Palo Alto

98003

Northwest Medical Specialties, PLLC, Federal Way

98332

Northwest Medical Specialties, PLLC, Gig Harbor

98373

Northwest Medical Specialties, PLLC, Puyallup

98391

Northwest Medical Specialties, PLLC, Bonney Lake

98405

Northwest Medical Specialties, PLLC, Tacoma

V5Z 1H7

BC Cancer Vancouver, Vancouver

V5Z 4E6

BC Cancer Vancouver, Vancouver

K1H 8L6

The Ottawa Hospital - General Campus, Ottawa

M4N 3M5

Sunnybrook Research Institute, Toronto

G7H 5H6

CIUSSS- saguenay-Lac-Saint-Jean, Chicoutimi

H3T 1E2

Jewish General Hospital, Montreal

00168

Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome

08035

Hospital Universitari Vall d'Hebron, Barcelona

08028

Hospital Universitari Dexeus, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Arvinas Estrogen Receptor, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY

NCT05548127 - TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) | Biotech Hunter | Biotech Hunter